中国药房2012，Vol.23Issue(26)：2401-2404,4.DOI:10.6039/j.issn.1001-0408.2012.26.01
舒尼替尼治疗转移性肾细胞癌患者的药物经济学评价
Pharmacoeconomic Evaluation of Sunitinib for the Treatment of Metastatic Renal Cell Carcinoma
杨怀勇 1杨龙 2许有威 3王璇4
作者信息
- 1. 云南省肿瘤医院药剂科,昆明 650118
- 2. 昆明医学院第一附属医院药剂科,昆明 650000
- 3. 大连医科大学药学院,辽宁大连116000
- 4. 第三军医大学第二附属医院药剂科,重庆400038
- 折叠
摘要
Abstract
OBJECTIVE: To evaluate the difference of sunitinib, sorafenib and interferon-α (IFN-α) in terms of health source utilization, treatment cost and health output, and to analyze the optimal cost-effectiveness and provide reference for reimbursement decision and clinical drug use decision. METHODS: A Markov model was developed by using Microsoft?Excel to simulate disease progression, cost and health outcomes over 5 years. Cost-effectiveness analysis was adopted for economic analysis of sunitinib, sorafenib and IFN-α for the first-line treatment of metastatic renal cell carcinoma. RESULTS: The reference case results indicated that, total average cost per capita of sunitinb group was higher than IFN-α group but lower than sorafenib group over 5 years; concerning health outcomes, obtained life year and quality adjusted life year of sunitinb group both were higher than those of sorafenib group and IFN-α group. CONCLUSION: Results suggest that sunitinib is not as cost-effective as IFN-α, but it is a cost-saving alternative to sorafenib.关键词
转移性肾细胞癌/药物经济学评价/成本-效果分析/舒尼替尼/索拉非尼/干扰素αKey words
Metastatic renal cell carcinoma/ Pharmacoeconomic evaluation/ Cost-effectiveness analysis/ Sunitinib/ Sorafenib/ lFN-α分类
医药卫生引用本文复制引用
杨怀勇,杨龙,许有威,王璇..舒尼替尼治疗转移性肾细胞癌患者的药物经济学评价[J].中国药房,2012,23(26):2401-2404,4.
